Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q2 2023 · 10-Q
Revenue$3.65M$3.65M−70.9% vs Q2 2022 Net Income-$304.33M-$304.33MN/M vs Q2 2022 EPS Diluted-$0.40-$0.40N/M vs Q2 2022 Operating Income-$213,891,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$196,702,000N/M Margins · derivedOperating margin-5863.2%−3623.0 pt vs Q2 2022
Net margin-8342.3%−6015.7 pt vs Q2 2022
ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end